Catherine Boule
Managing Partner @ Karista
Paris, France
Catherine Boule is a seed investor at Karista in Paris focused on Health Care and Biotechnology. Catherine Boule - Managing Partner @ Karista
- Total investments:
- 19
- Last investment:
- Lead investor:
- 16%
Last updated:
For AI agents: llms.txt
Industries Catherine Boule invests in
Stages Catherine Boule invests in
Countries Catherine Boule invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 7 (37%)
- Biotechnology 7 (37%)
- Medical 6 (32%)
- Medical Device 5 (26%)
- Therapeutics 3 (16%)
Stage
- Seed 10 (53%)
- Series A 3 (16%)
- Funding Round 2 (11%)
- Series B 1 (5%)
- Series C 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Healthcare professionals are now overwhelmed by the volume of patients and images. They need new tools. As safeguards of our Healthcare system, they need to be empowered and to participate in the AI production process. This is our mission through our co-creation projects. | $27.1M / Venture - Series Unknown / Sep 19, 2022 | ||
| Ludocare is to create ways to provide assistance to patients and their families to improve their abilities, autonomy, and quality of life. | $4.4M / Seed / Jul 04, 2022 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $7.7M / Series B / Nov 06, 2019 | ||
| Healthcare professionals are now overwhelmed by the volume of patients and images. They need new tools. As safeguards of our Healthcare system, they need to be empowered and to participate in the AI production process. This is our mission through our co-creation projects. | $6.2M / Seed / Sep 24, 2019 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $16.8M / Series B / Oct 17, 2018 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | Seed / Feb 07, 2017 | ||
| TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bindstrongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management. | $8.8M / Series A / Dec 09, 2013 | ||
| Incorporated in late 2005, VitamFero SA is a privately held biotech company whose mission, founded on an innovative and patented technology (i.e. Toxo KO), is to create, develop, register and market novel anti-infectious vaccines, first against Apicomplexe parasites such as:- Toxoplasma gondii (toxoplasmosis agent)- Neospora caninum(neosporosis agent)- Cryptosporidium parvum (cryptosporidiosis agent).With headquarters in Evry (France) and laboratories in Tours (France), VitamFero is involved first in veterinary healthcare. | Seed / Feb 21, 2011 | ||
| Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnosticof cancer. | $7.7M / Series C / May 05, 2010 | ||
| e(ye)BRAIN is a medical company that manufactures and distributes eye trackers for its clients.e(ye)BRAIN’s range of products include Eye Brain T1 and T2. The T1 enables its users to record eye movements. T2 uses algorithms to enable its users to record eye and head movements. The recorded movements will be analyzed by a software called MeyeEval.The company offers advisory, paradigm development, formation, and support services to its clients.e(ye)BRAIN was founded in 2008 by Serge Kinkingnehun and is based in France. | $1.8M / Series A / Nov 18, 2009 | ||
| See all 19 investments → | |||
Co-Investors
About Karista
Karista is an early-stage venture capital firm created in 2001. We funded 90+ companies over the past two decades and support tomorrow’s game changers in the field of Health, Digital, Tech, and NewSpace. We have always worked to provide more than cash and partnered with entrepreneurs whom we share a common vision with.
Karista Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Agathe Testu
Secretary General - RCCI
|
|||
Baudouin Hue
Partner
|
|||
Benjamin Zerbib
Investment Director
|
|||
|
Catherine Boule
Managing Partner
|
|||
Elodie Feraille
Management Assistant
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Catherine Boule invest in?
Catherine Boule invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Catherine Boule?
Public channels for Catherine Boule include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Catherine Boule last invest?
The most recent investment recorded for Catherine Boule closed in Sep 2022. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
